Liraglutide decreases carotid intima-media thickness in patients with type 2 diabetes: 8-month prospective pilot study

Decreased carotid atherosclerotic process by control of daily acute glucose fluctuations in diabetic patients treated by DPP-IV inhibitors

(2013) M. Barbieri et al.   ATHEROSCLEROSIS

Sagittal abdominal diameter is a more independent measure compared with waist circumference to predict arterial stiffness in subjects with type 2 diabetes - a prospective observational cohort study

(2013) Elsa M Dahlén et al.   Cardiovascular Diabetology

Effects of 24-week treatment with acarbose on glucagon-like peptide 1 in newly diagnosed type 2 diabetic patients: a preliminary report

(2013) Miao-yan Zheng et al.   Cardiovascular Diabetology

The GLP-1 receptor agonist liraglutide inhibits progression of vascular disease via effects on atherogenesis, plaque stability and endothelial function in an ApoE−/− mouse model

(2013) Tracey Gaspari et al.   Diabetes & Vascular Disease Research

Effects of 6 months glucagon-like peptide-1 receptor agonist treatment on endothelial function in type 2 diabetes mellitus patients

(2013) N. D. Hopkins et al.   DIABETES OBESITY & METABOLISM

Pioglitazone Slows Progression of Atherosclerosis in Prediabetes Independent of Changes in Cardiovascular Risk Factors

(2012) Aramesh Saremi et al.   ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY

Efficacy of liraglutide, a glucagon-like peptide-1 (GLP-1) analogue, on body weight, eating behavior, and glycemic control, in Japanese obese type 2 diabetes

(2012) Yuya Fujishima et al.   Cardiovascular Diabetology

Effects of GLP-1 on Forearm Vasodilator Function and Glucose Disposal During Hyperinsulinemia in the Metabolic Syndrome

(2012) M. Tesauro et al.   DIABETES CARE

A GLP-1 receptor agonist liraglutide inhibits endothelial cell dysfunction and vascular adhesion molecule expression in an ApoE-/- mouse model

(2011) Tracey Gaspari et al.   Diabetes & Vascular Disease Research

The Possible Protective Role of Glucagon-Like Peptide 1 on Endothelium During the Meal and Evidence for an "Endothelial Resistance" to Glucagon-Like Peptide 1 in Diabetes

(2011) A. Ceriello et al.   DIABETES CARE

A review of efficacy and safety data regarding the use of liraglutide, a once-daily human glucagon-like peptide 1 analogue, in the treatment of type 2 diabetes mellitus

(2010) Eduard Montanya et al.   CLINICAL THERAPEUTICS

The synthetic GLP-I receptor agonist, exenatide, reduces intimal hyperplasia in insulin resistant rats

(2010) Subramanyam N. Murthy et al.   Diabetes & Vascular Disease Research

GLP-1R Agonist Liraglutide Activates Cytoprotective Pathways and Improves Outcomes After Experimental Myocardial Infarction in Mice

(2009) M. H. Noyan-Ashraf et al.   DIABETES

Glucose lowering and anti-atherogenic effects of incretin-based therapies: GLP-1 analogues and DPP-4-inhibitors

(2009) Manfredi Rizzo et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Beneficial effects of once-daily liraglutide, a human glucagon-like peptide-1 analogue, on cardiovascular risk biomarkers in patients with Type 2 diabetes

(2008) J.-P. Courrèges et al.   DIABETIC MEDICINE